No GLP-1 medicine has been shown to cause the fewest side effects for everyone. In two direct weight-management trials, fewer people stopped weekly semaglutide than daily liraglutide because of an adverse event, and fewer stopped weekly tirzepatide than weekly semaglutide. Each comparison applies to its own trial. What matters for your decision is the kind of reaction you need to avoid, how much it disrupts your life, and what the prescriber can do if it happens.
What do you mean by “fewer side effects”?
Start with the outcome you care about. If nausea kept you from eating on a previous treatment, look for nausea data and ask what happened to people who had trouble continuing. If you’re concerned about a serious complication, the exact product warning and your history are more useful than a general nausea rate.
| What you want to know | What to look for |
|---|---|
| How common was the symptom? | The share of participants reporting that specific symptom |
| How disruptive was it? | Severity, duration, whether it came back and whether treatment changed |
| How often did people stop because of side effects? | Discontinuation attributed to adverse events, separate from stopping for any reason |
| Could this medicine be unsuitable for me? | Warnings and contraindications for the exact product, checked against your history |
An adverse event is a health problem reported during the study. Some events can occur for reasons unrelated to the study drug. If you want to identify symptoms before comparing tolerability, see the GLP-1 side-effects guide.
In direct trials, how often did people stop because of an adverse event?
Both trials below randomized adults with obesity or qualifying overweight and excluded people with diabetes. The numbers are comparisons between groups within the same study.
| Trial | Doses and duration | Stopped due to an adverse event |
|---|---|---|
| STEP 8 | Weekly semaglutide injection, target 2.4 mg, vs. daily liraglutide injection, target 3 mg, for 68 weeks | 3.2% vs. 12.6%, respectively |
| SURMOUNT-5 | Maximum tolerated weekly injections of tirzepatide (10 or 15 mg) vs. semaglutide (1.7 or 2.4 mg), for 72 weeks | 6.1% vs. 8.0%, respectively |
STEP 8 randomized trial · SURMOUNT-5 trial publication · SURMOUNT-5 discontinuation table
Why could digestive symptoms be equally common while more people stopped one medicine?
In STEP 8, 84.1% of people taking semaglutide and 82.7% of those taking liraglutide reported at least one digestive adverse event. That counts an event even if it passes and the person continues. The stopping figure captures a different part of the experience. Four of 126 people on semaglutide and 16 of 127 on liraglutide stopped because of adverse events.
The protocol also gave the groups different options when the target dose was hard to tolerate. Someone who couldn’t tolerate semaglutide 2.4 mg could remain at 1.7 mg. Someone who couldn’t tolerate liraglutide 3 mg had to discontinue, with the option of restarting escalation. The researchers identified this flexibility as one possible contributor to the stopping figures. If your main worry is being unable to tolerate a dose increase, what your prescriber can offer in that situation is part of the comparison. STEP 8 trial, methods and adverse events
Does the lower stopping rate make tirzepatide safer?
SURMOUNT-5 was designed to compare weight loss. Its stopping rates describe what happened in the two groups, and the study wasn’t powered to establish a safety or tolerability advantage. Both active-drug comparisons above were open-label, meaning participants and researchers knew the treatment. That can influence reporting and decisions about whether to continue.
Semaglutide’s stopping rate was 3.2% in one row and 8.0% in the other. That’s a practical test for a ranking you see online. If it uses the first number to place semaglutide above tirzepatide from the second row, the groups never competed under the same conditions. The same problem arises when a ranking combines label tables for different doses, routes or diabetes populations. SURMOUNT-5 sponsor reporting and study limitations · Wegovy prescribing information, section 6
What should you tell the prescriber if a previous GLP-1 was hard to tolerate?
Say what happened and what it prevented you from doing. “After my last increase, I vomited repeatedly and struggled to keep fluids down” gives the prescriber something to work with. If you know them, bring the brand, form, dose and date of the increase. Ask which findings apply to the proposed product, whom to contact if the problem returns, and what would trigger a review of the treatment plan. Confirm any dose change with the prescribing team.
Persistent or disruptive symptoms deserve a call to your care team. Some symptoms have a specific label instruction. The Wegovy and Zepbound medication guides say to stop the medicine and call your healthcare provider right away if you develop severe stomach-area pain that won’t go away, with or without nausea or vomiting. The pain may spread to the back and can be a sign of pancreatitis. Follow the instructions for the product you were prescribed. Wegovy medication guide · Zepbound medication guide

About the author
Maya Lee
Glowise Senior GLP-1 Content Editor
Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.
She helps readers ask better questions and keep the details relevant to a care conversation together.
See more Glowise on Google
Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.



